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Abstract:  
Mammary fibroepithelial lesions are biphasic neoplasms that comprise a wide spectrum of 
tumors ranging from indolent fibroadenomas to rare malignant phyllodes tumors. The 
histological distinction between the two on core needle biopsy can be challenging. Recently, 
TERT promoter mutations and gene amplifications have been used to differentiate 
fibroadenomas from phyllodes tumors. We present the case of a 59-year old woman initially 
diagnosed with a fibroepithelial lesion who refused surgery and presented 13 months later with 
a disfiguring borderline phyllodes tumor. Sequencing of the early fibroepithelial lesion and of 
the phyllodes tumor showed MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) 
somatic mutations, suggesting that the lesion was already a phyllodes tumor at time of the 
initial biopsy. The characterization of somatic mutations on core needle biopsy can help to 
better characterize fibroepithelial lesions and therefore increase diagnostic accuracy.  
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Clinical Practice points:  
• Breast fibroepithelial lesions comprise a wide spectrum of tumors ranging from indolent 
fibroadenomas to malignant phyllodes tumors. The histological distinction between the two 
on core needle biopsy can be challenging.  
• There is a need for molecular markers to better discriminate subclasses of breast 
fibroepithelial lesions on core needle biopsy to tailor clinical management.  
• Recently, TERT promoter mutations and gene amplifications have been used to 
differentiate fibroadenomas from phyllodes tumors.  
• This report describes a 59-year old woman diagnosed with a fibroepithelial lesion of the 
left breast who refused surgery and presented 13 months later with a disfiguring borderline 
phyllodes tumor that required mastectomy. Sequencing of the early FEL and of the PT 
showed MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) somatic mutations, 
suggesting that the lesion at time of the initial biopsy was already a phyllodes tumor.  
• The characterization of somatic mutations on core needle biopsy can help to better 
characterize fibroepithelial lesions and therefore increase diagnostic accuracy.   
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Introduction:  
Breast fibroepithelial lesions (FELs) are composed of biphasic proliferation of both epithelial 
and stromal elements and comprise a wide spectrum of tumors ranging from indolent 
fibroadenomas (FA) to malignant phyllodes tumors (PT).1 Whilst FAs are common benign 
tumors and are usually managed conservatively, PTs are rare (accounting for ~2.5% of all 
mammary FELs and for 1% of all breast cancers) and may recur locally or even metastasize 
to distant sites.1 
 
The histologic distinction between FAs and PTs on core needle biopsy (CNB) can be 
challenging.2 Pathologists may designate a FEL and add a comment of concern such as 
“cannot rule out phyllodes” or “increased stromal cellularity” if features of phyllodes are present 
but not definitive.3 However, the exact characterization of a FEL is clinically important as the 
management may range from observation to wide surgical resection (≥ 1cm margin).2,4 As it 
may be impossible to distinguish FA from benign or borderline PT on CNB due to overlapping 
histological features,2,3,5 excision is recommended in many patients resulting in potential 
overtreatment.2,5,6 A selective surgical approach based on clinical, radiological and 
pathological features is therefore recommended.4,7  
 
FAs and PTs share not only histologic similarities, but also genetic features.8 Recurrent 
somatic mutations affecting exon 2 of MED12 have been identified in both lesions.9-12 
Additionally, recent genomic analyses of FAs and PTs12 demonstrated that PTs are genetically 
more advanced and display a higher mutational burden than FAs.9 Furthermore, there have 
been reports of progression from FAs to PTs,8,13,14 with MED12 mutation as the founder genetic 
event and the subsequent acquisition of additional somatic genetic alterations such as TERT 
promoter mutations in the PTs.8  
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Here, we describe the case of a 59-year old woman initially diagnosed with a FEL with a TERT 
promoter mutation who refused surgery and presented 13 months later with a disfiguring 
borderline PT.  
Case report:  
In May 2016, a 59-year old woman with no personal history of breast or ovarian cancer was 
diagnosed with polymyositis. Clinical examination revealed an asymmetry of the left breast and 
a ~6 cm palpable mass on the upper external quadrant (Figure 1A) but no lymphadenopathies. 
Mammogram (Figure 1B) and ultrasound confirmed a 5.5x5cm mass in the upper external 
quadrant of the left breast and a 0.6x0.7 cm mass in the upper external quadrant of the right 
breast. CNB of both lesions was performed for diagnostic purposes. Histologic examination 
revealed a FA on the right side (classified as B2-lesion) (Figure 1C) and a FEL with increased 
stromal cellularity on the left side (classified as B3-lesion) (Figure 1D). Surgical excision of the 
FEL lesion was scheduled, but shortly before surgery the patient canceled the operation and 
was lost to follow up. 
 
Thirteen months later (June 2017), the patient presented to the emergency department with 
disfiguring swelling of the left breast (Figure 2A). On physical examination, the left breast was 
massively enlarged and tender with a flattened nipple, engorged superficial vessels, and 
deeply erythematous skin (Figure 2A). Breast ultrasound and MRI (Figure 2B) showed a 16 
cm heterogeneous mass filling the entire left breast with an extensive central fluid collection 
without suspected lymphadenopathies (Figure 2B). A diagnostic puncture of 1200 ml of bloody 
fluid was sent for cytology and microbiological tests that revealed no bacterial growth and no 
cellular atypia. CNB showed a myofibroblastic proliferation without an epithelial component. 
Differential diagnosis included a PT (stromal component only) or a non-specific reactive 
inflammatory process. After a multidisciplinary discussion, due to the large size of the tumor, 
mastectomy was performed. Based on the presence of focal stromal overgrowth, increased 
mitoses (7 per 10 HPF) and focally invasive tumor borders (Figure 2C-D), the diagnosis of a 
borderline PT was made on final histology. The patient recovered well, without complications. 
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Thirteen months after treatment, the patient continued to do well with no evidence of disease 
recurrence.  
 
To correlate the genomic profile of the tumor with its clinical evolution, massively parallel 
sequencing of 32 genes commonly altered in breast cancer (Supplementary Table 1) was 
performed, and analyzed as previously described,15 on tissues from the FA (right breast), the 
FEL and the PT (left breast). No somatic mutations were identified in any of the genes 
recurrently mutated in breast cancer. Subsequently, all three lesions were subjected to Sanger 
sequencing for the MED12 hotspot and for TERT promoter somatic mutations. Again, no 
mutation was identified in the FA in the right breast (Figure 3A). However, we identified a 
MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) mutations in both the early B3 
lesion and in the subsequent lesion after 13 months, suggesting the progression of the early 
lesion. This observation was further supported by their shared copy number alterations on 
chromosomes 11, 12 and 21, and the subsequent acquisition of copy number loss of AKT1 
and TP53 in the later lesion (Figure 3B). 
Discussion:  
This 59-year old woman was diagnosed with a FEL with increased stromal cellularity (B3-
lesion). The uncertain malignant potential was discussed with the patient in detail and surgical 
excision was scheduled. Given the absence of “cancer cells” on the CNB, the patient perceived 
the lesion as not dangerous. The patient canceled the scheduled operation and follow up was 
lost. The disfiguring evolution of the breast lesion and the inconclusive diagnosis on the second 
CNB 13 months later led to a mastectomy without reconstruction. 
  
Currently, there are no absolute criteria to recommend the excision of FELs when definitive 
diagnosis of a PT is not rendered after CNB.2,7 Many authors advocate reliance on pathologists’ 
comments and concordance assessment as important considerations to guide clinical 
management of FELs.3,16 Van Osdol et al. recently reported a sensitivity and specificity of 82% 
and 93% respectively for a pathologist comment of concern.7 Nevertheless, only 18-38% of 
 7 
patients who received excision for a FEL had a PT on definitive histology.3,17,18 The sometimes 
extreme difficulty to distinguish PTs from cellular FA, particularly in a limited tissue sample of 
a CNB, has also been acknowledged in the latest WHO classification,1 which states that in 
inconclusive cases, the diagnosis of a cellular fibroepithelial neoplasm may be appropriate, 
recognizing the inability to classify these lesions correctly19.  
 
Recently, it has been suggested that TERT alterations may assist in the differential diagnosis 
between FAs and PTs, as TERT promoter mutations and gene amplifications are frequent in 
PTs but are absent in FAs, and their frequency increases according to the grade of the PT 
(18% in benign, 57% in borderline and 64% in malignant PTs).8,20 Piscuoglio et al. concluded 
that sequencing and gene copy number analysis differentiate FAs from PTs with a 100% 
specificity and 100% positive predictive value.8 The finding of a TERT promoter mutation in the 
early B3 FEL on the left side would suggest it was also a PT. 
 
Genomic profiling has also furthered our understanding of the etiopathology of PTs. Pareja et 
al.21 have recently studied PTs with and without FA-like areas and hypothesized that borderline 
and malignant PTs might follow two distinct evolutionary pathways, according to MED12 
status. In the MED12-mutant pathway, MED12 exon 2 mutations are posited to lead to the 
development of a benign FEL, which, upon the occurrence of additional genetic alterations 
affecting TERT and/or other cancer gene, may progress to a borderline or malignant PT. In the 
MED12-independent pathway, borderline or malignant PTs might arise de novo, through 
acquisition of genetic alterations targeting cancer genes such as TERT and/or EGRF and other 
tumor suppressor genes.21 The presence of both the MED12 and TERT mutations in our 
current case would suggest it likely occurred through the MED12-mutant pathway, followed by 
the subsequent acquisition of the TERT promoter mutation, as well as additional copy number 
alterations. 
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The evolution from FA to PTs rarely occurs and has been reported in the literature as a slow 
process22,23. On the other hand, PTs are often reported as rapidly growing24. Whether growth 
rate differs according to the expression of MED12 is unknown. In the present case, the patient 
presented with a 5cm FEL, with MED12 and TERT promoter mutations, which rapidly evolved 
into a disfiguring borderline PT, which needed mastectomy.  
 
Conclusion:  
Recent studies have suggested that TERT promoter hotspot mutation and/or amplification may 
drive PT progression from a benign lesion such as FA, which represents an example of how 
genomic profiling may inform the clinical management of FELs. The current case demonstrates 
the natural course of a borderline PT after refusal of surgery. Knowing that the lesion had a 
TERT mutation and therefore a high likelihood of being a PT might have had encouraged the 
patient to undergo surgical excision and thus would have spared her the burden of a 
mastectomy. Further studies are needed to evaluate the impact of massively parallel 
sequencing on the outcome of patients with FELs.  
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Figures Legend 
Figure 1: Clinical, radiological and histological images at first presentation
A) Photo of the breast at first presentation 
B) Mammogram showing a 55x50mm mass on the left breast and a 6x7 mm mass on the right breast
C) Core needle biopsy of the right breast lesion showing a fibroepithelial lesion well demarcated from the surrounding 
tissue with low stromal cellularity, consistent with fibroadenoma (magnification 40x, H&E)
D) Core needle biopsy of the left breast lesion showing a fibroepithelial lesion with mildly increased stromal cellularity but
no stromal cell atypia (magnification 100x, H&E). 
Figure 2: Clinical, radiological and histological images 13 months after the first presentation 
A) Photo of the breast after 13 months 
B) Left: Axial fluid sensitive T2 – weighted MR image (TIRM). Right: Axial contrast-enhanced T1-weighted fat-suppressed MR 
image. Both images showing a 16 cm heterogeneous mass filling the entire left breast with an extensive central fluid 
collection 
C) Surgical specimen (mastectomy) of the left breast: showing a borderline phyllodes tumor with typical intracanalicular
“leaf-like” growth pattern and mildly increased, variable stromal cellularity (magnification 40x, H&E) 
D) Surgical specimen (mastectomy) of the left breast: areas reminiscent of a cellular fibroadenoma without stromal 
cellatypia (magnification 100x, H&E). 
Figure 3: Genetic profiling of the lesions
A) Sanger sequencing for the MED12 hotspot and for TERT promoter mutations. No somatic mutation was identified in the 
FA (right breast) whereas MED12 hotspot (c.131G>A) and TERT promoter (c.-124C>T) mutations were identified in both the 
early B3 lesion and in the PT (left breast). 
B) Copy number profiling of the 29 complete coding genes included in the targeted sequencing panel. No copy number 
alteration was identified in the FA (right breast). Gains of MALAT1, TBX3 and RUNX1 were found in both the early B3 lesion 
and in the PT (left breast). Addition losses of AKT1 and TP53 were found only in the lesion after 13 months.
